In the intricate web of bodily functions, cholesterol plays a crucial role as a type of fat or lipid. This essential substance is involved in the formation of cell membranes, the synthesis of various hormones, and the production of vitamin D within the body. Cholesterol is generated in two ways – through dietary intake and internal production by the liver. While cholesterol is integral to our physiological processes, an excess of it can pose serious health risks, especially in the form of low-density lipoprotein (LDL), commonly known as ‘bad’ cholesterol.
LDL cholesterol becomes a significant threat to life when it exceeds 100 mg per deciliter in the bloodstream. Unfortunately, the increase in its quantity often goes undetected, due to the lack of awareness among individuals. The consequences of elevated LDL cholesterol levels can manifest suddenly in the form of heart attacks or strokes, making its management crucial for cardiovascular health.
In the pursuit of addressing this health concern, KEM Hospital in Mumbai is currently conducting trials for a promising new medicine called Inclisiran. This medication has shown highly positive results during the trials and is touted as a potential game-changer in cholesterol management. Unlike existing medications that primarily aim to prevent further cholesterol increase, Inclisiran is positioned as a revolutionary solution that actively eliminates cholesterol from the body.
Inclisiran operates in the form of injections administered twice a year, offering a novel approach to cholesterol control. The Drug Controller General of India (DCGI) has approved Inclisiran, under the brand name of Sybrava, following the successful completion of trials. The injection’s cost is expected to be around Rs 1.2 lakhS. The potential impact on cardiovascular health may justify the investment for those at risk.
Dr Nityanand Tripathi, Head of the Cardiology Department at Fortis Hospital in New Delhi, shed light on the mechanics of Inclisiran. This innovative medication targets the PCSK9 protein, a key player in the liver responsible for increasing LDL cholesterol synthesis. By inhibiting the PCSK9 protein pathway, Inclisiran effectively halts the production of cholesterol, providing a unique and potent solution to managing cholesterol levels.
While existing medications like Repatha also aim to reduce LDL cholesterol, Inclisiran stands out due to its twice-a-year injection schedule, offering convenience and potentially improving patient adherence. The reduction of cholesterol by even 1 mg with inclisiran corresponds to a significant 2 per cent reduction in the risk of heart disease, highlighting its potential as a breakthrough in cardiovascular health management.
As the world awaits regulatory approval for inclisiran, its arrival could herald a new era in cholesterol management, offering a more effective and convenient solution for individuals striving to protect their cardiovascular well-being.
Comments
0 comment